Kala Bio (FRA:27F) Moat Score: 3/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:27F Kala Bio Inc FRA:27F
18 GF Score
Price €3.40
! 2 Warning Signs
View Full Analysis

What is Kala Bio Moat Score?

Kala Bio FRA:27F 18 Moat Score is 3 as of Jul. 18, 2026. GuruFocus rates FRA:27F with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Kala Bio ranks better than 75.57% on this metric.

Kala Bio has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Kala Bio has No Moat: Kala Bio operates in a competitive biotech industry with limited market share and customer loyalty. The company lacks significant intellectual property or cost advantages, and faces high R&D costs and regulatory hurdles, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kala Bio might have No Moat - Very weak/transient advantages.

Kala Bio  (FRA:27F) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kala Bio Moat Score Related Terms

FRA:27F vs MGX, HYPD, VERU: Moat Score Comparison

For the Biotechnology subindustry, Kala Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kala Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where Kala Bio's Moat Score falls into.


FRA:27F
18GF Score
Kala Bio Inc FRA:27F
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Kala Bio (FRA:27F) has a Moat Score of 3 as of Jul. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kala Bio ranks #341 out of 1396 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Kala Bio's Moat Score too high?
Kala Bio's current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Kala Bio's value of 3 is 50% above this industry median. Based on the distribution chart, Kala Bio ranks #341 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kala Bio has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Kala Bio's Moat Score compare to MGX and HYPD?
According to the Biotechnology industry distribution chart, Kala Bio ranks #341 out of 1396 companies for Moat Score. This places Kala Bio in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Kala Bio's value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kala Bio's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kala Bio's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kala Bio stock overvalued right now?
Kala Bio (FRA:27F) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Kala Bio's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kala Bio (FRA:27F), the current Moat Score is 3 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kala Bio Business Description

Other Exchanges KALA:USA0JQ2:UK27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
18GF Score

Get the complete analysis for FRA:27F

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price